Figure 6.
High ferroptosis score is more sensitive to vinorelbine chemotherapy, ICB therapy, and anti-CTLA4 immunotherapy
Boxplots depicted the differences in the estimated IC50 levels of (A) sorafenib, (B) sunitinib, (C) cisplatin, (D) gefitinib, (E) vinblastine, (F) vinorelbine, (G) vorinostat, and (H) gemcitabine between the high and low ferroptosis score groups. (I) Boxplots showed the differences in TIDE scores between the two groups. (J) Heatmap visualized the response to anti-CTLA4 and anti-PD1 therapies between the two groups.